Widely used:Recently Viewed
Clear AllQuality Score 
0/0
Growth Score
0/0
Valuation Score
0/0
Momentum Score
0/0
Today’s Range
52 Week Range
Liquidity
Market cap
$23 Mln
P/E Ratio
--
P/B Ratio
0.99
Industry P/E
--
Debt to Equity
0
ROE
-0.56 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
-0.98
CFO
$-125.72 Mln
EBITDA
$-131.81 Mln
Net Profit
$-153.73 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Enlivex Therapeutics - ADR
| -11.97 | 0.98 | -8.85 | -28.47 | -43.82 | -28.62 | -41.86 |
|
BSE Sensex
| 2.61 | 3.71 | 5.78 | 8.89 | 11.76 | 20.11 | 11.35 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|
|---|---|---|---|---|---|---|---|
|
Enlivex Therapeutics - ADR
| -31.43 | -36.99 | -25.86 | 0.46 | 35.56 | -65.95 | -56.04 |
|
S&P Small-Cap 600
| 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 | 11.73 |
|
BSE Sensex
| 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 | 27.91 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 2.25 | 25.43 | -- | -79.46 | |
| 1.44 | 138.40 | -- | -23.63 | |
| 2.25 | 109.01 | -- | -103.34 | |
| 11.13 | 466.01 | -- | 342.83 |
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ... dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel. Read more
Executive Chairman
Mr. Shai Novik M.B.A.
Executive Chairman
Mr. Shai Novik M.B.A.
Headquarters
Ness Ziona
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Enlivex Therapeutics Ltd - ADR stood at $ 33 Mln as on 30-Sep-24
The share price of Enlivex Therapeutics Ltd - ADR is $1.03 (NASDAQ) as of 29-Apr-2025 13:43 EDT. Enlivex Therapeutics Ltd - ADR has given a return of -43.82% in the last 3 years.
Enlivex Therapeutics Ltd - ADR has a market capitalisation of $ 23 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Enlivex Therapeutics Ltd - ADR is 0.99 times as on 25-Apr-2025, a 73% discount to its peers’ median range of 3.61 times.
Since, TTM earnings of Enlivex Therapeutics Ltd - ADR is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Enlivex Therapeutics Ltd - ADR and enter the required number of quantities and click on buy to purchase the shares of Enlivex Therapeutics Ltd - ADR.
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra, which is in phase II clinical trial for the treatment of organ dysfunction caused by sepsis. The company also develops Allocetra for the treatment of moderate knee osteoarthritis and end-stage knee osteoarthritis which is in phase I/II clinical trial. Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.
The CEO & director of Mr. Shai Novik M.B.A.. is Enlivex Therapeutics Ltd - ADR, and CFO & Sr. VP is Mr. Shai Novik M.B.A..
There is no promoter pledging in Enlivex Therapeutics Ltd - ADR.
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
48
|
|
|
15
|
|
|
8
|
|
|
5
|
| Enlivex Therapeutics Ltd. - ADR | Ratios |
|---|---|
|
Return on equity(%)
|
-70.86
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Enlivex Therapeutics Ltd - ADR was $0 Mln.
